NCT06564194View on ClinicalTrials.gov

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Respiratory Syncytial Virus (RSV)Infectious Disease
Interventions
BIOLOGICAL

JCXH-108

IM injection

OTHER

Placebo

IM injection

Trial Locations (3)

33458

Health Awareness, Jupiter

63131

Sundance Clinical Research, St Louis

70115

DelRicht - New Orleans, New Orleans

Sponsors
All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Immorna Biotherapeutics, Inc.

INDUSTRY